Home › Compare › SPRJ vs ABBV

SPRJ vs ABBV: Dividend Comparison 2026

SPRJ yields 30303.03% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPRJ wins by $3.263808061549561e+21M in total portfolio value
10 years
SPRJ
SPRJ
● Live price
30303.03%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.263808061549561e+21M
Annual income
$3,242,757,379,434,520,500,000,000,000.00
Full SPRJ calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SPRJ vs ABBV

📍 SPRJ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPRJABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPRJ + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SPRJ pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPRJ
Annual income on $10K today (after 15% tax)
$2,575,757.58/yr
After 10yr DRIP, annual income (after tax)
$2,756,343,772,519,342,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SPRJ beats the other by $2,756,343,772,519,342,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPRJ + ABBV for your $10,000?

SPRJ: 50%ABBV: 50%
100% ABBV50/50100% SPRJ
Portfolio after 10yr
$1.6319040307747805e+21M
Annual income
$1,621,378,689,717,260,200,000,000,000.00/yr
Blended yield
99.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SPRJ
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPRJ buys
0
ABBV buys
0
No recent congressional trades found for SPRJ or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPRJABBV
Forward yield30303.03% ✓3.06%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$3.263808061549561e+21M$102.3K ✓
Annual income after 10y$3,242,757,379,434,520,500,000,000,000.00 ✓$24,771.77
Total dividends collected$3.2624231116646724e+21M$61.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPRJ vs ABBV ($10,000, DRIP)

YearSPRJ PortfolioSPRJ Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$3,041,003$3,030,303.03$11,550$430.00+$3.03M → SPRJ
2$864,483,845$861,229,971.77$13,472$627.96+$864.47M → SPRJ
3$229,735,200,804$228,810,203,089.76$15,906$926.08+$229735.18M → SPRJ
4$57,073,803,532,538$56,827,986,867,677.43$19,071$1,382.55+$57073803.51M → SPRJ
5$13,255,411,832,905,296$13,194,342,863,125,480.00$23,302$2,095.81+$13255411832.88M → SPRJ
6$2,878,100,090,729,619,500$2,863,916,800,068,411,000.00$29,150$3,237.93+$2878100090729.59M → SPRJ
7$584,230,965,528,377,800,000$581,151,398,431,297,240,000.00$37,536$5,121.41+$584230965528377.75M → SPRJ
8$110,876,546,219,110,120,000,000$110,251,419,085,994,750,000,000.00$50,079$8,338.38+$110876546219110112.00M → SPRJ
9$19,673,534,686,953,956,000,000,000$19,554,896,782,499,505,000,000,000.00$69,753$14,065.80+$19673534686953955328.00M → SPRJ
10$3,263,808,061,549,561,000,000,000,000$3,242,757,379,434,520,500,000,000,000.00$102,337$24,771.77+$3.263808061549561e+21M → SPRJ

SPRJ vs ABBV: Complete Analysis 2026

SPRJ — Stock

Springs Rejuvenation, LLC offers aging and stem repair services. The company is based in the United States.

Full SPRJ Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SPRJ vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPRJ vs SCHDSPRJ vs JEPISPRJ vs OSPRJ vs KOSPRJ vs MAINSPRJ vs JNJSPRJ vs MRKSPRJ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.